What Happens When You Stop Mounjaro, Ozempic or Wegovy?

Search for what happens when you stop a GLP-1 and you get two headlines that seem to contradict each other. One says most of the weight comes back within a year. The other says a study of almost 8,000 people found barely any regain at all.

Both are accurate. They describe different people doing different things after the injections stop, and the gap between them is the most useful thing to understand before you come off. Here is what the evidence actually shows, and what you can do about it.

What the trials show

The cleanest evidence comes from trials that took people who had lost weight and then switched some of them, without their knowledge, to a placebo.

• Semaglutide (Wegovy, Ozempic). In STEP 4, people switched to placebo after 20 weeks regained 6.9% of their body weight over the next 48 weeks, while those who stayed on it lost a further 7.9%. In the STEP 1 extension, people who had lost 17.3% regained 11.6 percentage points in the year after stopping: about two-thirds of what they had lost.
• Tirzepatide (Mounjaro, Zepbound). In SURMOUNT-4, people lost 20.9% over 36 weeks. Those switched to placebo regained 14% of their body weight over the following year and finished 9.9% below where they started, against 25.3% for those who stayed on it. Only 16.6% of the placebo group kept at least 80% of their loss.

A follow-up analysis of SURMOUNT-4 looked at 308 people who had lost at least 10% before being switched to placebo. 82.5% of them regained at least a quarter of what they had lost within a year.

That is the honest baseline. Stopping, with nothing else changing, reliably brings a large share of the weight back.

It slows down, and it usually stops short

What the headline numbers hide is the shape of the curve.

A 2026 analysis pooling six trials of 3,236 people modelled regain over time. It was fastest early on and then slowed steadily, with a half-life of about 23 weeks. About 60% of lost weight had returned after one year, and the curve levelled off at around 75%: below the starting weight, not back at it.

The largest review so far, 37 studies and 9,341 people in The BMJ, found regain after semaglutide and tirzepatide averaged 0.8 kg a month, and projected a return to starting weight in about a year and a half. The two analyses model regain differently, one projecting a full return and the other a plateau, but they agree on the part that matters most for you: regain is fastest in the first months after stopping.

Why real-world numbers look so different

Then there is the Cleveland Clinic study of 7,938 people who stopped semaglutide or tirzepatide, which found that people treated for obesity were only 0.5% heavier a year after stopping. That sounds like it contradicts everything above. It doesn't, for three reasons.

1. They had lost less. Everyone in the study stopped within 3 to 12 months of starting, having lost 8.4% on average, far short of the 17 to 21% in the trials. There was less to regain.
2. Many didn't simply stop. Within the year, 19.6% restarted the same medication and 27.4% started a different one. A trial's placebo group has none of that.
3. It's routine care, not a controlled test. The study couldn't record why people stopped, and people in routine care stop for many different reasons and do very different things next.

So the real-world study isn't evidence that regain doesn't happen. It's evidence that what you do after stopping changes the outcome, which is the useful part.

What comes back with the weight

Weight isn't the only thing that rebounds.

• Health markers follow the scale. In the SURMOUNT-4 follow-up, blood pressure, cholesterol and blood sugar worsened in step with how much weight came back. The BMJ review projected all the cardiometabolic markers it measured to be back at baseline within 1.4 years of stopping.
• The weight that returns skews towards fat. In a study of postmenopausal women regaining weight after intentional weight loss, they had lost 0.26 kg of lean tissue for every kilo of fat lost, but regained only 0.12 kg of lean tissue for every kilo of fat regained. That study wasn't in GLP-1 users, but the pattern is why repeated cycles of losing and regaining can leave you softer at the same weight.

Why it happens

A GLP-1 works while it is in your system. When it stops:

• Appetite returns. Fullness takes longer to arrive and hunger comes back sooner, so portions drift up without you deciding they should.
• Food noise can come back. The background thinking about food that the medication quietened often returns within weeks.
• You need less energy than before. A smaller body burns less, so the margin between maintaining and gaining is narrower than it was before you started.

None of this is willpower failing. It's the medication's effect wearing off in a body that tends to defend its previous weight, which is why obesity is treated as a long-term condition rather than something a single course of treatment fixes.

What reduces the regain

The best evidence for protecting your result points to what you build while you are still on the medication.

• Train while you're on it. In a Danish trial that followed people for a year after treatment ended, those whose treatment had been supervised exercise regained about 6 kg less than those whose treatment had been a GLP-1 on its own, and kept their body composition. Start with how to train on a GLP-1.
• Keep protein high. It helps with returning hunger and protects lean tissue, which matters more once you know regained weight tends to be fat. Set your number with the protein calculator and the protein targets guide.
• Make the structure automatic before you stop. Regular protein-first meals, a shopping routine, a fixed training slot in your week. When appetite returns, habits that are already in place do some of the work the medication was doing.
• Watch the trend and act early. Weigh yourself on a schedule and look at the trend across weeks, not the daily number. Correcting a two-kilo drift is far easier than correcting a ten-kilo one.

The full step-by-step plan is in how to keep weight off after stopping.

Stopping, tapering, or staying on

Stopping isn't the only option, and it isn't necessarily the goal.

• Staying on a maintenance dose is a legitimate, evidence-based choice. In SURMOUNT-4, people who continued kept losing weight rather than regaining it.
• Tapering is appealing but largely untested. Modelling work suggests that dosing every two weeks might keep around three-quarters of the weight effect, but that is a simulation, not a trial, and no study has yet compared tapering with stopping outright.
• Stopping because of cost or supply is common. If that is your situation, the steps above matter even more, and it's worth asking your prescriber about alternatives before your last dose rather than after it.

Any change to your dose, including stopping, belongs with your prescriber.

If you've already stopped

Regaining some weight after stopping is the expected outcome, not a personal failure. What matters is noticing early. If your trend is rising, tighten the basics first: protein back up, meals back to a regular rhythm, training back in the diary. If it keeps climbing, talk to your prescriber. In the Cleveland Clinic data, one in five people restarted their medication within a year, and that is a normal clinical decision, not a setback.

A note on the evidence: the trial figures come from people switched to placebo in a controlled setting, while the real-world study reflects routine care in one US health system. Your own result will depend on how much you lost, how long you were treated, and what you do next.

This is general nutrition information and educational content, not medical advice. Don't stop or change a prescribed medication without talking to your prescriber.